Pneumococcal Vaccines The Impact Of Conjugate Vaccine

Size: px
Start display at page:

Download "Pneumococcal Vaccines The Impact Of Conjugate Vaccine"

Transcription

1 Pneumococcal Vaccines The Impact Of Conjugate Vaccine 1 / 5

2 2 / 5

3 3 / 5

4 Pneumococcal Vaccines The Impact Of Pneumococcal vaccine. The pneumococcal vaccine protects against serious and potentially fatal pneumococcal infections. It's also known as the "pneumo jab" or pneumonia vaccine. Pneumococcal infections are caused by the bacterium Streptococcus pneumoniae and can lead to pneumonia, septicaemia (a kind of blood poisoning) and meningitis. Pneumococcal vaccine - NHS Side effects of the pneumococcal vaccine in adults and older children Mild side effects of the pneumococcal polysaccharide vaccine (PPV), the version of the pneumococcal vaccine given to adults and children over the age of 2, include: Pneumococcal vaccine side effects - NHS Buy Pneumococcal Vaccines: The Impact of Conjugate Vaccine 1 by George R Siber, Keith P Klugman, P. Helena Mäkelä (ISBN: ) from Amazon's Book Store. Everyday low prices and free delivery on eligible orders. Pneumococcal Vaccines: The Impact of Conjugate Vaccine... These are the 13-valent pneumococcal conjugate vaccine (PCV13) and the 23-valent pneumococcal polysaccharide vaccine (PPV23). Current recommendations for both vaccines can be found in the Green Book. Pneumococcal disease: guidance, data and analysis - GOV.UK There are two vaccines available to protect children from pneumococcal disease, a serious infection caused by a bacterium known as Streptococcus pneumoniae. Only one of the vaccines, PCV13, is... Pneumococcal Vaccine Schedule and Side Effects - WebMD Pneumococcal vaccines are vaccines against the bacteria Streptococcus pneumoniae. Their use can prevent some cases of pneumonia, meningitis, and sepsis. There are two types of pneumococcal vaccines: conjugate vaccines and polysaccharide vaccines. They are given by injection either into a muscle or just under the skin. Pneumococcal vaccine - Wikipedia Pneumococcal vaccines. Safe and affordable vaccines are the most effective way to prevent pneumococcal infection. WHO recommends that all countries introduce pneumococcal vaccines in their immunisation programmes. This is particularly important in countries with high levels of child mortality. Pneumococcal vaccine support - Gavi, the Vaccine Alliance Pneumococcal infections elicited by Streptococcus pneumoniae (pneumococcus) (pneumonia, otitis media, sinusitis, meningitis) are frequently occurring diseases that are associated with considerable morbidity and mortality even in developed countries. Pneumococcal vaccines: mechanism of action, impact on... Pneumococcal disease is common in young children, but older adults are at greatest risk of serious illness and death. There are two kinds of vaccines that help prevent pneumococcal disease. CDC recommends pneumococcal vaccination for all children younger than 2 years old and all adults 65 years or Pneumococcal Vaccination What You Should Know CDC As with any vaccine, you may experience some mild side effects after receiving the pneumococcal vaccine. Mild side effects vary depending on which vaccine you receive. 4 / 5

5 Powered by TCPDF ( the impact of tourism on employment and economic development the, double impact comic, environmental impacts of coal mining and utilization 5 / 5

Streptococcus pneumoniae CDC

Streptococcus pneumoniae CDC Streptococcus pneumoniae CDC Pneumococcal Disease Infection caused by the bacteria, Streptococcus pneumoniae» otitis media 20 million office visits (28-55% Strep)» pneumonia 175,000 cases annually» meningitis

More information

Pneumococcal (PPV) immunisation uptake in Wales 2006 Surveillance Report, October 2006

Pneumococcal (PPV) immunisation uptake in Wales 2006 Surveillance Report, October 2006 Pneumococcal (PPV) immunisation uptake in Wales 2006 Surveillance Report, October 2006 Key Findings In July 2006, uptake of pneumococcal vaccination amongst those aged 65 years and over in Wales, immunised

More information

Setting The setting was primary care. The economic study was carried out in Norway.

Setting The setting was primary care. The economic study was carried out in Norway. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program Wisloff T, Abrahamsen T G, Bergsaker M A, Lovoll O, Moller P, Pedersen M K, Kristiansen

More information

To view past issues, go to: The New 13-Valent Pneumococcal Conjugate Vaccine (PCV13)

To view past issues, go to:   The New 13-Valent Pneumococcal Conjugate Vaccine (PCV13) From the Texas Department of State Health Services Immunization Branch The goal of the Vaccine Advisory is to disseminate, in a timely manner, practical information related to vaccines, vaccine-preventable

More information

Pneumococcal vaccination in UK: an update. Dr Richard Pebody Immunisation Department Health Protection Agency Centre for Infections

Pneumococcal vaccination in UK: an update. Dr Richard Pebody Immunisation Department Health Protection Agency Centre for Infections Pneumococcal vaccination in UK: an update Dr Richard Pebody Immunisation Department Health Protection Agency Centre for Infections Leading infectious causes of mortality, 2000 WHO estimates 3.5 Deaths

More information

Benefits of the pneumococcal immunisation programme in children in the United Kingdom

Benefits of the pneumococcal immunisation programme in children in the United Kingdom Benefits of the pneumococcal immunisation programme in children in the United Kingdom 2006-2014 Professor Mary P E Slack mpeslack@gmail.com March 2015 Disclosure of interest The presenter has received

More information

Pneumococcal Disease and Pneumococcal Vaccines

Pneumococcal Disease and Pneumococcal Vaccines Pneumococcal Disease and Epidemiology and Prevention of - Preventable Diseases Note to presenters: Images of vaccine-preventable diseases are available from the Immunization Action Coalition website at

More information

Bacterial diseases caused by Streptoccus pneumoniae in children

Bacterial diseases caused by Streptoccus pneumoniae in children Bacterial diseases caused by Streptoccus pneumoniae in children Bactermia 85% Bacterial pneumonia 66% Bacterial meningitis 50% Otitis media 40% Paranasal sinusitis 40% 0% 10% 20% 30% 40% 50% 60% 70% 80%

More information

The use of total funds channelled through "la Caixa" to Gavi programmes in 2017

The use of total funds channelled through la Caixa to Gavi programmes in 2017 The use of total funds channelled through "la Caixa" to Gavi programmes in 2017 Final Report to the la Caixa Foundation (for Gavi) July 2018 www.gavi.org Executive Summary The la Caixa Foundation and GAVI

More information

Impact of vaccination on epidemiology in adults

Impact of vaccination on epidemiology in adults Impact of vaccination on epidemiology in adults Jan Verhaegen 1. Data on prospective study on IPD in Belgium (2009-2011) 2. Evolution of capsular types of invasive isolates from adults after introduction

More information

Haemophilus influenzae

Haemophilus influenzae Haemophilus influenzae type b Severe bacterial infection, particularly among infants During late 19th century believed to cause influenza Immunology and microbiology clarified in 1930s Haemophilus influenzae

More information

Report of Typing & Antimicrobial Susceptibilities of Isolates Causing Invasive Pneumococcal Disease in Ireland,

Report of Typing & Antimicrobial Susceptibilities of Isolates Causing Invasive Pneumococcal Disease in Ireland, Report of Typing & Antimicrobial Susceptibilities of Isolates Causing Invasive Pneumococcal Disease in Ireland, 2011-2013 1. Background Streptococcus pneumoniae is a major cause of life-threatening infections

More information

BCG vaccine and tuberculosis

BCG vaccine and tuberculosis PART 2: Vaccination for special risk groups 2.1 Vaccination for Aboriginal and Torres Strait Islander people Aboriginal and Torres Strait Islander people historically had a very high burden of infectious

More information

GENERAL PRACTITIONER DATA PACK GUIDANCE

GENERAL PRACTITIONER DATA PACK GUIDANCE RESTRICTED For CQC internal use only This should NOT be shared outside CQC GENERAL PRACTITIONER DATA PACK GUIDANCE PRIMARY CARE DATA PACKS AND INSPECTION TEAM - November 2015 - Table of Contents Introduction...

More information

NHS public health functions agreement

NHS public health functions agreement NHS public health functions agreement 2016-17 Service specification No.7 Hib/MenC vaccination programme NHS England INFORMATION READER BOX Directorate Medical Commissioning Operations Patients and Information

More information

Chapter 16 Pneumococcal Infection. Pneumococcal Infection. August 2015

Chapter 16 Pneumococcal Infection. Pneumococcal Infection. August 2015 Chapter 16 16 PPV introduced for at risk 1996 PCV7 introduced for at risk 2002 and as routine 2008 PCV13 replaced PCV7 in 2010 NOTIFIABLE In some circumstances, advice in these guidelines may differ from

More information

Pneumococcal vaccination for older persons. No. 2018/05. Executive summary

Pneumococcal vaccination for older persons. No. 2018/05. Executive summary Pneumococcal vaccination for older persons No. 2018/05 Executive summary Executive summary Pneumococcal vaccination for older persons page 2 of 6 Many people carry pneumococcal bacteria without becoming

More information

2017/18 Immunisation programmes list of additional and enhanced services

2017/18 Immunisation programmes list of additional and enhanced services 2017/18 Immunisation programmes list of additional and enhanced services 2017/18 Vaccination and Immunisation list of additional and enhanced services Version number: 1 First published: April 2017 Prepared

More information

2016/17 Vaccination and Immunisation list of additional services and enhanced services

2016/17 Vaccination and Immunisation list of additional services and enhanced services 2016/17 Vaccination and Immunisation list of additional services and enhanced services 2016/17 Vaccination and Immunisation list of additional services and enhanced services Version number: 1 First published:

More information

2018/19 Immunisation programmes list of additional and enhanced services

2018/19 Immunisation programmes list of additional and enhanced services 2018/19 Immunisation programmes list of additional and enhanced services 2018/19 Vaccination and Immunisation list of additional and enhanced services Version number: 1 First published: April 2018 Prepared

More information

Measure #111 (NQF 0043): Pneumococcal Vaccination Status for Older Adults National Quality Strategy Domain: Community/Population Health

Measure #111 (NQF 0043): Pneumococcal Vaccination Status for Older Adults National Quality Strategy Domain: Community/Population Health Measure #111 (NQF 0043): Pneumococcal Vaccination Status for Older Adults National Quality Strategy Domain: Community/Population Health 2017 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY MEASURE TYPE: Process

More information

Splenectomy Vaccine Protocol PIDPIC

Splenectomy Vaccine Protocol PIDPIC Splenectomy Vaccine Protocol PIDPIC 6.24.14 Rationale Spleen clears encapsulated bacteria and infected erythrocytes Serves as one of the largest lymphoid tissues where B cells are educated against encapsulated

More information

Patient & Family Guide. Pneumovax 23. (Pneumococcal Vaccine Polyvalent) and Kidney Disease.

Patient & Family Guide. Pneumovax 23. (Pneumococcal Vaccine Polyvalent) and Kidney Disease. Patient & Family Guide 2018 Pneumovax 23 (Pneumococcal Vaccine Polyvalent) and Kidney Disease www.nshealth.ca Pneumovax 23 (Pneumococcal Vaccine Polyvalent) and Kidney Disease What is Pneumovax 23? Pneumovax

More information

Annual Epidemiological Report

Annual Epidemiological Report August 2018 Annual Epidemiological Report Key Facts Streptococcus 1Pneumoniae (invasive) in Ireland, 2017 In 2017, 415 confirmed cases of invasive pneumococcal diseases (IPD) were reported in Ireland,

More information

EARSS in Ireland, Results of invasive Streptococcus pneumoniae infection (blood/csf) surveillance

EARSS in Ireland, Results of invasive Streptococcus pneumoniae infection (blood/csf) surveillance EARSS in Ireland, 2007 Results of invasive Streptococcus pneumoniae infection (blood/csf) surveillance Antibiotic codes and abbreviations: CTX, Ciprofloxacin ERY, Erythromycin OXA, Oxacillin TCY, Tetracycline

More information

Monitoring results: goals, strategic objectives and indicators

Monitoring results: goals, strategic objectives and indicators page 108 Monitoring results: goals, strategic objectives and indicators 6. SURVEILLANCE Strategic Objective 4: strong immunization sytems are an integral part of a well-functioning health system. Indicator

More information

Pneumococcal Vaccine Introductions Dr. Carsten Mantel WHO/FCH/IVB/EPI

Pneumococcal Vaccine Introductions Dr. Carsten Mantel WHO/FCH/IVB/EPI Pneumococcal Vaccine Introductions 2012 Dr. Carsten Mantel WHO/FCH/IVB/EPI Pneumonia is leading cause of death in children < 5 yrs * Pneumococcus and Hib are the two leading causes of life-threatening

More information

Patient & Family Guide. Prevnar 13. (Pneumococcal Conjugate Vaccine) and Kidney Disease.

Patient & Family Guide. Prevnar 13. (Pneumococcal Conjugate Vaccine) and Kidney Disease. Patient & Family Guide 2018 Prevnar 13 (Pneumococcal Conjugate Vaccine) and Kidney Disease www.nshealth.ca Prevnar 13 (Pneumococcal Conjugate Vaccine) and Kidney Disease What is Prevnar 13? Prevnar 13

More information

GAVI Alliance Demand-side Innovation Policies

GAVI Alliance Demand-side Innovation Policies GAVI Alliance Demand-side Innovation Policies Presentation at the Multi-year Expert Meeting on Investment, Innovation and Entrepreneurship for Productive Capacity-building and Sustainable Development Lauren

More information

Potential Impact of Conjugate Vaccine on the Incidence of Invasive Pneumococcal Disease among Children in Scotland

Potential Impact of Conjugate Vaccine on the Incidence of Invasive Pneumococcal Disease among Children in Scotland JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 2006, p. 1224 1228 Vol. 44, No. 4 0095-1137/06/$08.00 0 doi:10.1128/jcm.44.4.1224 1228.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved.

More information

PNEUMONIA : PROMISE FULFILLED? Regina Berba MD FPSMID

PNEUMONIA : PROMISE FULFILLED? Regina Berba MD FPSMID PNEUMONIA : PROMISE FULFILLED? Regina Berba MD FPSMID Objectives of Lecture Know the quality of current evidence based guidelines on immunization Appreciate the performance of pneumonia vaccines in terns

More information

Measure #111 (NQF 0043): Pneumonia Vaccination Status for Older Adults National Quality Strategy Domain: Community/Population Health

Measure #111 (NQF 0043): Pneumonia Vaccination Status for Older Adults National Quality Strategy Domain: Community/Population Health Measure #111 (NQF 0043): Pneumonia Vaccination Status for Older Adults National Quality Strategy Domain: Community/Population Health 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION:

More information

Surveillance of invasive pneumococcal infection in Belgium

Surveillance of invasive pneumococcal infection in Belgium Surveillance of invasive pneumococcal infection in Belgium National Reference Laboratory Start in 198 Laboratory Microbiology UH Leuven (prof. J. Vandepitte) Capsular type determination Antibiotic susceptibility

More information

Source of effectiveness data The effectiveness data were derived from a review or synthesis of completed studies.

Source of effectiveness data The effectiveness data were derived from a review or synthesis of completed studies. The 23-valent pneumococcal polysaccharide vaccine. Part II: a cost-effectiveness analysis for invasive disease in the elderly in England and Wales Melegaro A, Edmunds W J Record Status This is a critical

More information

Shabir A. Madhi. Progress and Challenges of Immunization Contributing Toward Attaining the MDG Goal to Reduce under-5 Childhood Mortality.

Shabir A. Madhi. Progress and Challenges of Immunization Contributing Toward Attaining the MDG Goal to Reduce under-5 Childhood Mortality. Shabir A. Madhi Progress and Challenges of Immunization Contributing Toward Attaining the MDG Goal to Reduce under-5 Childhood Mortality. National Institute for Communicable Diseases & University of Witwatersrand,

More information

Setting The setting was community. The economic study was carried out in the USA.

Setting The setting was community. The economic study was carried out in the USA. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children Lieu T A, Ray G T, Black S R, Butler J C, Klein J O, Breiman R F, Miller M A, Shinefield H R Record

More information

14/10/16. Background. Streptococcus pneumoniae (Sp) is an important cause for these diseases

14/10/16. Background. Streptococcus pneumoniae (Sp) is an important cause for these diseases Estimates of the potential public health impact and cost-effectiveness of adopting pneumococcal vaccination in the routine immunization programme in African GAVI countries: a modelling study C. Sauboin

More information

NHS public health functions agreement Service specification No.6 Meningococcal C (MenC) containing vaccine immunisation programme

NHS public health functions agreement Service specification No.6 Meningococcal C (MenC) containing vaccine immunisation programme NHS public health functions agreement 2018-19 Service specification No.6 Meningococcal C (MenC) containing vaccine immunisation programme 1 NHS public health functions agreement 2018-19 Service specification

More information

KEEP WARM, KEEP WELL THIS WINTER

KEEP WARM, KEEP WELL THIS WINTER KEEP WARM, KEEP WELL THIS WINTER SO, KEEP WARM... Keeping warm can help reduce your risk of colds and flu, as well as more serious problems such as heart attacks, strokes, pneumonia and depression. If

More information

Getting national guidelines into practice: It takes more than education

Getting national guidelines into practice: It takes more than education Getting national guidelines into practice: It takes more than education AI Collaborative Group 2 September 12, 2017 Lynette M. Wachholz, MN, ARNP, CPHQ Email: lwachholz@everettclinic.com The Everett Clinic

More information

Why is surveillance important after introducing vaccines?

Why is surveillance important after introducing vaccines? Why is surveillance important after introducing vaccines? Dr Michael Edelstein Immunisation Department, National Infections service Public Health England @epi_michael BSAC Spring conference, 12 th March

More information

Invasive pneumococcal disease

Invasive pneumococcal disease SURVEILLANCE REPORT Annual Epidemiological Report for 2016 Invasive pneumococcal disease Key facts In 2016, 21 986 confirmed cases of invasive pneumococcal disease (IPD) were reported in the EU/EEA. The

More information

9/12/2018. Pneumococcal Disease and Pneumococcal Vaccines. Streptococcus pneumoniae. Pneumococcal Disease. Adult Track. Gram-positive bacteria

9/12/2018. Pneumococcal Disease and Pneumococcal Vaccines. Streptococcus pneumoniae. Pneumococcal Disease. Adult Track. Gram-positive bacteria Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Pneumococcal Disease and Pneumococcal Vaccines Adult Track Chapter 17 Photographs and images included

More information

Risk profiles and vaccine uptake in children with invasive pneumococcal disease at a tertiary hospital in Tshwane:

Risk profiles and vaccine uptake in children with invasive pneumococcal disease at a tertiary hospital in Tshwane: Risk profiles and vaccine uptake in children with invasive pneumococcal disease at a tertiary hospital in Tshwane: A retrospective review Xandré Dearden www.up.ac.za IPD: disease spectrum and epidemiology

More information

PDF of Trial CTRI Website URL -

PDF of Trial CTRI Website URL - Clinical Trial Details (PDF Generation Date :- Fri, 23 Nov 2018 06:48:34 GMT) CTRI Number Last Modified On 18/02/2015 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study

More information

Health technology Four strategies for the control of serogroup C meningococcal disease (CMD) were examined. These were:

Health technology Four strategies for the control of serogroup C meningococcal disease (CMD) were examined. These were: Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease De Wals P, Nguyen V H, Erickson L J, Guay M, Drapeau J, St-Laurent J Record Status This is a critical

More information

Pneumococcal vaccines. Safety & Efficacy. Prof. Rajesh Kumar, MD PGIMER School of Public Health Chandigarh

Pneumococcal vaccines. Safety & Efficacy. Prof. Rajesh Kumar, MD PGIMER School of Public Health Chandigarh Pneumococcal vaccines Safety & Efficacy Prof. Rajesh Kumar, MD PGIMER School of Public Health Chandigarh Disclosure Slide X X I DO NOT have any significant or other financial relationships with industry

More information

ACIP Recommendations for Pneumococcal 13-valent Conjugate and 23-valent Polysaccharide Vaccine Use among Adults

ACIP Recommendations for Pneumococcal 13-valent Conjugate and 23-valent Polysaccharide Vaccine Use among Adults ACIP Recommendations for Pneumococcal 13-valent Conjugate and 23-valent Polysaccharide Vaccine Use among Adults National Center for Immunization & Respiratory Diseases Respiratory Diseases Branch ACIP

More information

EPIREVIEW INVASIVE PNEUMOCOCCAL DISEASE, NSW, 2002

EPIREVIEW INVASIVE PNEUMOCOCCAL DISEASE, NSW, 2002 EPIREVIEW INVASIVE PNEUMOCOCCAL DISEASE, NSW, 2002 Robyn Gilmour Communicable Diseases Branch NSW Department of Health BACKGROUND Infection with the bacterium Streptococcus pneumoniae is a major cause

More information

Study population The study population comprised the general population of Senegal inhabitants aged 1 to 30 years.

Study population The study population comprised the general population of Senegal inhabitants aged 1 to 30 years. Comparison of cost-effectiveness of preventive and reactive mass immunization campaigns against meningococcal meningitis in West Africa: a theoretical modeling analysis Parent du Chatelet I, Gessner B

More information

the benefits and potential side effects of pneumococcal immunization; and

the benefits and potential side effects of pneumococcal immunization; and F883 483.80(d) Influenza and pneumococcal immunizations 483.80(d)(1) Influenza. The facility must develop policies and procedures to ensure that- (i) Before offering the influenza immunization, each resident

More information

Health technology Pneumococcal polysaccharide vaccination was compared with no vaccination.

Health technology Pneumococcal polysaccharide vaccination was compared with no vaccination. Cost effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race Sisk J E, Whang W, Butler J C, Sneller V-P, Whitney

More information

Outsourcing in Clinical Trials 1-2 July 2015

Outsourcing in Clinical Trials 1-2 July 2015 Outsourcing in Clinical Trials 1-2 July 2015 Innovating Dr Chris Bailey Babraham Research Campus Babraham Cambridge CB22 3AT UK +44 (0)1223 496115 Vaccines www.immbio.com 1 Utilising Academia for the Benefit

More information

Invasive Pneumococcal Disease Quarterly Report

Invasive Pneumococcal Disease Quarterly Report Invasive Pneumococcal Disease Quarterly Report April June 2018 Prepared as part of a Ministry of Health contract for scientific services by Liza Lopez Helen Heffernan July 2018 Acknowledgements This report

More information

A national study of the epidemiology of pneumococcal disease among hospitalised patients in Singapore: 1995 to 2004

A national study of the epidemiology of pneumococcal disease among hospitalised patients in Singapore: 1995 to 2004 O r i g i n a l A r t i c l e Singapore Med J 2007; 48 (9) : 824 A national study of the epidemiology of pneumococcal disease among hospitalised patients in Singapore: 1995 to 2004 Low S, Chan F L F, Cutter

More information

Can infant vaccination prevent pneumococcal meningitis outbreaks in sub-saharan Africa?

Can infant vaccination prevent pneumococcal meningitis outbreaks in sub-saharan Africa? Editorial Can infant vaccination prevent pneumococcal meningitis outbreaks in sub-saharan Africa? Author: James M Stuart, FFPH London School of Hygiene and Tropical Medicine, Keppel St, London WC1E 7HT,

More information

Cost-effectiveness of vaccination against pneumococcal pneumonia in The Netherlands Baltussen R M, Ament A J, Leidl R M, Van Furth R

Cost-effectiveness of vaccination against pneumococcal pneumonia in The Netherlands Baltussen R M, Ament A J, Leidl R M, Van Furth R Cost-effectiveness of vaccination against pneumococcal pneumonia in The Netherlands Baltussen R M, Ament A J, Leidl R M, Van Furth R Record Status This is a critical abstract of an economic evaluation

More information

Additional files. English version of questionnaire, April 3, 2014

Additional files. English version of questionnaire, April 3, 2014 Additional files English version of questionnaire, April 3, 2014 Individual questionnaire You are invited to participate in a survey of parents. This survey is sponsored by the Shanghai Centers for Disease

More information

Incidence per 100,000

Incidence per 100,000 Streptococcus pneumoniae Surveillance Report 2005 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Department of Human Services Updated: March 2007 Background

More information

Type of intervention Treatment. Economic study type Cost-effectiveness analysis.

Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Nonsevere acute otitis media: a clinical trial comparing outcomes of watchful waiting versus immediate antibiotic treatment McCormick D P, Chonmaitree T, Pittman C, Saeed K, Friedman N R, Uchida T, Baldwin

More information

2018 CMS Web Interface

2018 CMS Web Interface CMS Web Interface PREV-8: Pneumococcal Vaccination Status for Older AdultsMeasure Steward: NCQA CMS Web Interface V2.1 Page 1 of 18 06/25/ Contents INTRODUCTION...3 CMS WEB INTERFACE SAMPLING INFORMATION...4

More information

Recommendations for Using Pneumococcal Vaccines among Adults

Recommendations for Using Pneumococcal Vaccines among Adults Recommendations for Using Pneumococcal Vaccines among Adults AI Collaborative Webinar July 2017 Tamara Pilishvili Respiratory Diseases Branch, CDC National Center for Immunization & Respiratory Diseases

More information

VERSION APPROVAL PROCESS NUMBER 1.0 Nina Schwalbe, Managing Director, Policy and Performance

VERSION APPROVAL PROCESS NUMBER 1.0 Nina Schwalbe, Managing Director, Policy and Performance Version No.: 1.0 Page 1 / 5 DOCUMENT ADMINISTRATION VERSION APPROVAL PROCESS DATE NUMBER 1.0 Nina Schwalbe, Managing Director, and Performance Reviewed by: GAVI Programme 23 April 2012 and Committee Approved

More information

Economic evaluation of Haemophilus influenzae type b vaccination in Slovenia Pokorn M, Kopac S, Neubauer D, Cizman M

Economic evaluation of Haemophilus influenzae type b vaccination in Slovenia Pokorn M, Kopac S, Neubauer D, Cizman M Economic evaluation of Haemophilus influenzae type b vaccination in Slovenia Pokorn M, Kopac S, Neubauer D, Cizman M Record Status This is a critical abstract of an economic evaluation that meets the criteria

More information

Global Evolution of the Pneumococcus and the Impact of Vaccination Keith P. Klugman

Global Evolution of the Pneumococcus and the Impact of Vaccination Keith P. Klugman Global Evolution of the Pneumococcus and the Impact of Vaccination Keith P. Klugman Department of Global Health, Rollins School of Public Health and Division of Infectious Diseases, School of Medicine

More information

Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model

Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model Aggarwal R, Ghoshal U C, Naik S R Record Status This is

More information

WHO posi)on paper on pneumococcal vaccines. Geneva, Switzerland Published in the Weekly Epidemiological Record on 6 Apr 2012

WHO posi)on paper on pneumococcal vaccines. Geneva, Switzerland Published in the Weekly Epidemiological Record on 6 Apr 2012 WHO posi)on paper on pneumococcal vaccines Geneva, Switzerland Published in the Weekly Epidemiological Record on 6 Apr 2012 WHO posi)on paper on pneumococcal vaccines, April 2012 The current posi)on paper

More information

CONJUGATE VACCINES A BREAKTHROUGH IN VACCINE DEVELOPMENT

CONJUGATE VACCINES A BREAKTHROUGH IN VACCINE DEVELOPMENT CONJUGATE VACCINES A BREAKTHROUGH IN VACCINE DEVELOPMENT P Helena Mäkelä National Public Health Institute, Helsinki, Finland Abstract. The encapsulated bacteria Streptococcus pneumoniae (the pneumococcus),

More information

Immunology and the middle ear Andrew Riordan

Immunology and the middle ear Andrew Riordan Immunology and the middle ear Andrew Riordan The Immune system is NOT there; To baffle medical students To keep Immunologists in a job To encourage experiments on mice The Immune system IS there as a defence

More information

Classification: official 1

Classification: official 1 NHS public health functions agreement 2018-19 Service specification No.4 Immunisation against diphtheria, tetanus, poliomyelitis, pertussis, Hib and HepB programme 1 NHS public health functions agreement

More information

Pneumococcal polysaccharide vaccine uptake in England, , prior to the introduction of a vaccination programme for older adults

Pneumococcal polysaccharide vaccine uptake in England, , prior to the introduction of a vaccination programme for older adults Journal of Public Health Advance Access published July 7, 2006 Journal of Public Health pp. 1 of 6 doi:10.1093/pubmed/fdl017 Pneumococcal polysaccharide vaccine uptake in England, 1989 2003, prior to the

More information

CUMULATIVE INVASIVE PNEUMOCOCCAL DISEASE CASE NUMBERS REPORTED BY THE GERMS-SA SURVEILLANCE PROGRAMME, 2005 TO DATE

CUMULATIVE INVASIVE PNEUMOCOCCAL DISEASE CASE NUMBERS REPORTED BY THE GERMS-SA SURVEILLANCE PROGRAMME, 2005 TO DATE CUMULATIVE INVASIVE PNEUMOCOCCAL DISEASE CASE NUMBERS REPORTED BY THE GERMS-SA SURVEILLANCE PROGRAMME, 5 TO DATE GERMS-SA surveillance programme http://www.nicd.ac.za/?page=germs-sa&id=97 National, active,

More information

Recommendations for Using Pneumococcal Vaccines among Adults

Recommendations for Using Pneumococcal Vaccines among Adults Recommendations for Using Pneumococcal Vaccines among Adults AI Collaborative Webinar February 2016 Tamara Pilishvili Respiratory Diseases Branch, CDC National Center for Immunization & Respiratory Diseases

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Management of meningitis and meningococcal disease in children and young people in primary and secondary care. 1.1 Short title

More information

Full public health impact or. cherry-picking?

Full public health impact or. cherry-picking? Full public health impact or cherry-picking? Arto Palmu, MD, PhD, Research manager, head of Clinical Research Team, Department of Public Health Solutions 10.11.2017 Arto Palmu / RIVM2017 1 Disclosure The

More information

Childhood Pneumonia & Meningitis: Recent Advances

Childhood Pneumonia & Meningitis: Recent Advances Childhood Pneumonia & Meningitis: Recent Advances Karachi, Pakistan January 31, 2009 MEDIA COVERAGE DAWN KARACHI, Pakistan February 1, 2009 Experts pin hopes on pentavalent vaccines A programme to introduce

More information

41 Pneumococcal Disease

41 Pneumococcal Disease 41 Pneumococcal Disease Epidemiology and Prevention Abstract: Streptococcus pneumonie is a major cause of morbidity and mortality in very young, high-risk adults and elderly population. It kills almost

More information

Economic Evaluation. Defining the Scope of a Costeffectiveness

Economic Evaluation. Defining the Scope of a Costeffectiveness Economic Evaluation Defining the Scope of a Costeffectiveness Analysis II This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes

More information

If these vaccines haven t been given, please follow guidelines below for emergency procedures.

If these vaccines haven t been given, please follow guidelines below for emergency procedures. MANAGEMENT OF PATIIENTS POST SPLENECTOMY & HYPOSPLENIIC PATIIENTS Splenectomised and hyposplenic patients are at increased risk of life-threatening infections due to encapsulated micro-organisms such as

More information

...REPORTS... Epidemiology of Pneumococcal Disease/ Rationale for and Efficacy of PnC7

...REPORTS... Epidemiology of Pneumococcal Disease/ Rationale for and Efficacy of PnC7 ...REPORTS... Epidemiology of Pneumococcal Disease/ Rationale for and Efficacy of PnC7 Summary A Streptococcus pneumoniae Conjugate Vaccine Managed Care Advisory Panel was presented with information on

More information

NA NA NA NA NA ,

NA NA NA NA NA , Kansas Spotlight: Prevention This report describes prevention in three distinct categories: Access to Health Care, Immunizations (coverage), and Chronic Disease Prevention. Access Dedicated Health Care

More information

Vaccine Efficacy IPD and Pneumonia

Vaccine Efficacy IPD and Pneumonia Vaccine Efficacy IPD and Pneumonia Hanna Nohynek, MD PhD National Public Health Institute Helsinki, Finland for 3rd Regional Pneumococcal Symposium Istanbul, Turkey February 13-14, 2008 Vaccine efficacy

More information

Adult Pneumococcal Disease

Adult Pneumococcal Disease Adult Pneumococcal Disease S. pneumoniae and pneumococcal disease The bacterium Streptococcus pneumoniae causes pneumococcal disease S. pneumoniae is commonly found in human nasopharynx (nose and throat)

More information

Craig Laferriere. The selection of pneumococcal serotypes for a developing-world vaccine: A metaregression analysis of immunogenicity

Craig Laferriere. The selection of pneumococcal serotypes for a developing-world vaccine: A metaregression analysis of immunogenicity Craig Laferriere The selection of pneumococcal serotypes for a developing-world vaccine: A metaregression analysis of immunogenicity I have no actual or potential conflict of interest in relation to this

More information

Invasive Pneumococcal Disease Quarterly Report

Invasive Pneumococcal Disease Quarterly Report Invasive Pneumococcal Disease Quarterly Report January March 2018 Prepared as part of a Ministry of Health contract for scientific services by Rebekah Roos Helen Heffernan June 2018 Acknowledgements This

More information

The power of partnership: the GAVI Alliance Board

The power of partnership: the GAVI Alliance Board The power of partnership: the GAVI Alliance Board 1 GAVI s mission To save children s lives and protect people s health by increasing access to immunisation in poor countries Strategic goals 2011 2015!

More information

Economic Evaluation of a Universal Childhood Pneumococcal Conjugate Vaccination Strategy in Ireland

Economic Evaluation of a Universal Childhood Pneumococcal Conjugate Vaccination Strategy in Ireland Volume 11 Number 5 2008 VALUE IN HEALTH Economic Evaluation of a Universal Childhood Pneumococcal Conjugate Vaccination Strategy in Ireland Lesley Tilson, BSc (Pharm), PhD, 1 Cara Usher, BSc, PhD, 1 Karina

More information

As One Of Canada s Top Killers, Why Isn t Pneumonia Taken More Seriously?

As One Of Canada s Top Killers, Why Isn t Pneumonia Taken More Seriously? As One Of Canada s Top Killers, Why Isn t Pneumonia Taken More Seriously? $ $ $ March, 2019 Table of Contents 02 04 06 10 24 27 32 41 44 Improving Vaccination Rates What Are Our Governments Doing To Improve

More information

NHS public health functions agreement Service specification No. 31 Meningococcal group B (MenB) programme

NHS public health functions agreement Service specification No. 31 Meningococcal group B (MenB) programme NHS public health functions agreement 2017-18 Service specification No. 31 Meningococcal group B (MenB) programme Classification: official NHS public health functions agreement 2017-18 Service specification

More information

The English immunization programme

The English immunization programme The English immunization programme Mary Ramsay Head of Immunisation Public Health England National Health Service Constitution (2009) You have the right to receive the vaccinations that the Joint Committee

More information

Pneumococcal Pneumonia

Pneumococcal Pneumonia 2 Pneumococcal Pneumonia Pneumococcal Pneumonia Pneumonia is infection in the lungs which makes them wet and inflamed. Secretions block off the small air sacs and oxygen is not able to move from the inhaled

More information

Streptococcus Pneumoniae

Streptococcus Pneumoniae Streptococcus Pneumoniae (Invasive Pneumococcal Disease) DISEASE REPORTABLE WITHIN 24 HOURS OF DIAGNOSIS Per N.J.A.C. 8:57, healthcare providers and administrators shall report by mail or by electronic

More information

CLINICAL CONTENT OF PATIENT GROUP DIRECTION FOR PNEUMOCOCCAL CONJUGATE VACCINE (Prevenar 13 )

CLINICAL CONTENT OF PATIENT GROUP DIRECTION FOR PNEUMOCOCCAL CONJUGATE VACCINE (Prevenar 13 ) Patient Group Direction for Pneumococcal Conjugate Vaccine (Prevenar 13 ) Version: PNEUMOCOCCAL CONJUGATE 2014.1 Start 1 st February 2014 Expiry 31 st January 2017 THIS PATIENT GROUP DIRECTION HAS BEEN

More information

PROCEEDINGS of the Second Regional Pneumococcal Symposium. Hotel Sofitel Sao Paulo São Paulo, Brazil December 13 14, 2006

PROCEEDINGS of the Second Regional Pneumococcal Symposium. Hotel Sofitel Sao Paulo São Paulo, Brazil December 13 14, 2006 PROCEEDINGS of the Second Regional Pneumococcal Symposium Hotel Sofitel Sao Paulo São Paulo, Brazil December 13 14, 2006 Acknowledgements The Symposium Organizing Committee wishes to thank the following

More information

Sadistic Killers Profiles Of Pathological Predators

Sadistic Killers Profiles Of Pathological Predators Sadistic Killers Profiles Of Pathological Predators 1 / 6 2 / 6 3 / 6 Sadistic Killers Profiles Of Pathological Acclaimed crime writer Carol Anne Davis explores the minds of sadistic killers: their childhoods,

More information

Vaccination Guidelines Sipho Dlamini Division of Infectious Diseases & HIV Medicine University of Cape Town Groote Schuur Hospital

Vaccination Guidelines Sipho Dlamini Division of Infectious Diseases & HIV Medicine University of Cape Town Groote Schuur Hospital Vaccination Guidelines Sipho Dlamini Division of Infectious Diseases & HIV Medicine University of Cape Town Groote Schuur Hospital 4 th Southern African HIV Clinicians Society Conference / 24-27 October

More information

IID&GHTP. Pneumococcal vaccine Africa décembre By: Julie Lajoie

IID&GHTP. Pneumococcal vaccine Africa décembre By: Julie Lajoie IID&GHTP Pneumococcal vaccine Africa décembre 2011 By: Julie Lajoie General information Ecology and Epidemiology of invasive pneumococcal disease (IPD) in sub Saharan Africa is different from that seen

More information

Pneumococcal polysaccharide vaccines: Systematic review and meta-analysis of randomised controlled efficacy trials

Pneumococcal polysaccharide vaccines: Systematic review and meta-analysis of randomised controlled efficacy trials Pneumococcal polysaccharide vaccines: Systematic review and meta-analysis of randomised controlled efficacy trials Pippa Scott, Anke Huss, Matthias Egger Institute of Social & Preventive Medicine (ISPM)

More information

Pneumococcal vaccines

Pneumococcal vaccines Pneumococcal vaccines Marco Aurélio Sáfadi, MD, PhD FCM da Santa Casa de São Paulo Challenges in establishing the baseline burden of disease, before implementing a vaccination program S. pneumoniae disease

More information

Cost-effectiveness of routine immunization to control Japanese encephalitis in Shanghai, China Ding D, Kilgore P E, Clemens J D, Liu W, Xu Z Y

Cost-effectiveness of routine immunization to control Japanese encephalitis in Shanghai, China Ding D, Kilgore P E, Clemens J D, Liu W, Xu Z Y Cost-effectiveness of routine immunization to control Japanese encephalitis in Shanghai, China Ding D, Kilgore P E, Clemens J D, Liu W, Xu Z Y Record Status This is a critical abstract of an economic evaluation

More information